India, May 28 -- Drugmaker GSK plc (GSK) on Tuesday announced positive Phase III trial results for investigational hepatitis B treatment bepirovirsen.
Pooled data from the Phase III B-Well 1 and B-Well 2 trials showed that 19% of patients receiving bepirovirsen achieved a functional cure, compared with 0% in the placebo group.
Among patients with lower baseline viral activity, defined as hepatitis B surface antigen levels of 1,000 IU/mL or less, the functional cure rate increased to 26%, also versus 0% for placebo.
GSK said current standard therapies typically require lifelong treatment and achieve functional cure rates in less than 1% of patients.
The company also reported that 23% of all bepirovirsen-treated patients achieved sustaine...